Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
Authors
Keywords
Lung squamous cell carcinoma, Genome, TMB, PD-L1, Immune cells
Journal
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-12
DOI
10.1186/s13045-019-0762-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients
- (2019) Xu-Chao Zhang et al. Nature Communications
- Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung
- (2018) Tatsuro Okamoto et al. ANNALS OF SURGICAL ONCOLOGY
- Clinical and Pathological Characteristics ofKEAP1- andNFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
- (2018) Rieke Frank et al. CLINICAL CANCER RESEARCH
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report
- (2018) Yuki Owada-Ozaki et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma
- (2017) Kazuki Takada et al. LUNG CANCER
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
- (2017) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications
- (2017) Yu-Pei Chen et al. Theranostics
- Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer
- (2017) Hui Yang et al. Cancer Medicine
- Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy
- (2017) Roberto Chalela et al. Journal of Thoracic Disease
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
- (2016) C.-Y. Ock et al. CLINICAL CANCER RESEARCH
- Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
- (2016) Takaaki Tokito et al. EUROPEAN JOURNAL OF CANCER
- Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer
- (2016) Elisabeth Brambilla et al. JOURNAL OF CLINICAL ONCOLOGY
- Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment
- (2016) Corey J. Langer et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
- (2015) D. R. Gandara et al. CLINICAL CANCER RESEARCH
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?
- (2013) Julie R. Brahmer SEMINARS IN ONCOLOGY
- Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
- (2012) P. Perez-Moreno et al. CLINICAL CANCER RESEARCH
- Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer
- (2009) Rodrigo Arriagada et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More